Back to search

National and Kapodistrian University of Athens

Φαρμακευτική παρέμβαση στις μεταβολικές και ορμονικές διαταραχές και στους δείκτες καρδιαγγειακού κινδύνου στις γυναίκες με σύνδρομο πολυκυστικών ωοθηκών

Abstract

dc:description

Background : Current knowledge on the pathophysiology of polycystic ovary syndrome (PCOS) has created a new framework for the treatment of the syndrome, which includes the need for amelioration of atherogenic markers which may be elevated in women with the syndrome. The costs and benefits of two most commonly prescribed pharmaceutical treatments in PCOS, oral contraceptives (OCPs) and metformin have been studied in this framework. Metformin appears to alleviate the cardiovascular risk associated with PCOS, while OCPs may have a neutral or aggravating effect on atherogenic markers.Objective: The present work compares the effects of two types of OCPs and metformin on atherogenic markers, including serum levels of Advanced Glycated End products (AGEs) and C-reactive protein (CRP), in lean women with PCOS.Design: Prospective open-label study Results: One hundred and twenty women with PCOS were treated for six months with one of the following treatments: ethinylestradiol plus cyproterone acetate (OCP 1) or ethinylestradiol plus drospirenone (OCP2) or metformin (MET). The three groups were matched for age and body mass index (BMI). At six months serum AGEs were decreased in all groups, but the decrease was greater with metformin. Treatment with metformin was associated with a greater percent decrease of AGEs. CRP was decreased with metformin, but increased with OCPs, to a greater degree with OCP1 compared to OCP2. Conclusions: This study attempts to evaluate common therapeutic options in women with PCOS by reconsidering and prioritizing the goals of treatment. OCPs and metformin appear to have differential effects on atherogenic molecules in lean PCOS patients, but metformin was superior in reducing serum AGEs and CRP. Clinicians should individualise the benefit-to-risk ratio of pharmaceutical intervention in women with PCOS, in order to choose the formulation with the greatest efficacy and safety in terms of cardiovascular risk.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Christakou, Charikleia
  • Χρηστάκου, Χαρίκλεια

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38496

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Christakou, Charikleia; Χρηστάκου, Χαρίκλεια. Φαρμακευτική παρέμβαση στις μεταβολικές και ορμονικές διαταραχές και στους δείκτες καρδιαγγειακού κινδύνου στις γυναίκες με σύνδρομο πολυκυστικών ωοθηκών. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/38496